Last reviewed 2026-04-23 · How we verify

TQB2102 Injection

TQB2102 Injection's mechanism is not publicly available.

TQB2102 Injection's mechanism is not publicly available. Used for Phase 3 for TQB2102 Injection is not publicly available..

At a glance

Mechanism of action

Unfortunately, there is limited information available on the exact mechanism of action of TQB2102 Injection.

Approved indications

• Phase 3 for TQB2102 Injection is not publicly available.

Common side effects

No common side effects on file.

Key clinical trials

• A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
• A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs (PHASE3)
• A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer (PHASE1, PHASE2)
• A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality (PHASE2)
• A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE2)
• Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer (PHASE3)
• Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers (PHASE1)
• A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.